What investment strategy does TechLife Capital focus on?

TechLife Capital focuses on Growth strategies in the private equity space.

How many portfolio companies does TechLife Capital have?

TechLife Capital has 11 active portfolio companies and 2 completed exits and 2 funds tracked on GP Intel.

Where is TechLife Capital headquartered?

TechLife Capital is headquartered in Paris, France.

What is TechLife Capital's assets under management?

TechLife Capital manages approximately €150M in assets under management.

When was TechLife Capital founded?

TechLife Capital was founded in 2018.

What sectors does TechLife Capital invest in?

TechLife Capital invests across Healthcare, Software, Business Services.

Home/GPs/TechLife Capital

TechLife Capital

Paris, France·Founded 2018·

Growth Equity

·techlifecapital.com

Paris-based growth-equity PE firm founded 2018 focused on Healthcare and Technology mid-market scale-ups; deploys around EUR 150M across TechLife Capital I (2018 EUR 100M flagship) and TechLife Capital II (2024 EUR 50M proxy),…Read full bio

AUM

€150M

Funds

Portfolio

Exits

SectorsHealthcareSoftwareBusiness Services

Key facts

HQParis, France

Founded2018

Websitetechlifecapital.com

Recent exits

Maxxing

TMT · 2025

Atempo

TMT · 2025

Coverage notes

2 funds tracked, 13 portfolio companies (11 active · 2 realized). Verified weekly from public filings and deal announcements.

About TechLife Capital

TechLife Capital is a Paris-based growth equity private equity firm with €150 million of assets under management, founded in 2018 and focused on Healthcare and Technology mid-market scale-ups. The firm deploys across TechLife Capital I (vintage 2018, €100M flagship) and TechLife Capital II (vintage 2024, €50M proxy), with AMF registration and Tibi label alignment supporting institutional French limited partner relationships.

Investment thesis

TechLife Capital targets European Healthcare and Technology mid-market scale-ups, deploying growth equity capital with equity tickets typically ranging from €5 million to €20 million per transaction. Sector focus spans HealthTech, MedTech, enterprise software and selective B2B technology verticals, with the dual healthcare-technology mandate enabling cross-vertical insights into digital health and HealthTech innovation themes.

Recent activity

Recent realised exits include Atempo (TMT, 2025) and Maxxing (TMT, 2025), reflecting active distribution across the technology portfolio. The platform tracks 2 funds, 11 active portfolio companies and 2 realised exits across the multi-vintage healthcare and technology growth equity programme. Detailed buyer names and multiple data available on Pro at €49/month.